|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||3.92 - 4.45|
|52 Week Range||0.46 - 5.80|
|Beta (3Y Monthly)||3.50|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
NORWOOD, MA, Nov. 20, 2018 (GLOBE NEWSWIRE) -- MariMed Inc. (MRMD), a multi-state cannabis operator, reported third quarter 2018 financial results for the quarter and nine months ended September 30, 2018. The Company continued to grow quarterly year-over-year revenue since the second quarter of 2016. Operating income increased 75% to approximately $2.0 from approximately $1.1 million during the nine months ended September 30, 2017.
When the market is volatile, investors flee to safety. Often, investors will retreat out of growth names and into more established industries. We saw that trend play out in October on the over-the-counter ...
A new company is set to join the growing hemp market. MariMed Inc (OTC: MRMD ) has agreed to invest $30 million in GenCanna Global as part of a strategic partnership. What Happened MariMed develops and ...
WINCHESTER, KY and NEWTON, MA, Nov. 12, 2018 (GLOBE NEWSWIRE) -- MariMed Inc. (MRMD) and GenCanna Global Inc. (“GenCanna”) jointly announced today that the companies have entered into an agreement whereby MariMed has invested $30 million in GenCanna, and the companies have created a strategic partnership, including a long-term supply agreement. The partnership expands MariMed’s robust product development capabilities and strengthens GenCanna’s position as a global leader in the Hemp CBD industry.
When the dust settled from the midterm elections, President Donald Trump did something both shocking and inevitable: he fired Attorney General Jeff Sessions. Occupying a contentious tenure from the start, Sessions passive-aggressively clashed with Trump by recusing himself from the Russian-meddling inquiry. Political insiders characterized Sessions as having a “tough sheriff” personality.
CORAL GABLES, FL / ACCESSWIRE / November 7,2018 / Medical cannabis and recreational marijuana have been put in a very bright spotlight on Wednesday. Missouri and Utah approved medical marijuana initiatives, joining 31 other states that already allow prescription sales. ICC International Cannabis Corp. (KNHBF) (WRLD) a has held its trading level around $0.50 for the last week and on the heels of major marijuana market developments, the company announced today that it has received an inaugural purchase order for 10,000mL of Tetrahydrocannabinol Cannabis oil, 5,000g of dried Cannabis flower and 5,000mL of Cannabidiol oil.
Finnie to lead MariMed M&A, strategic investment, corporate strategy, investor relations Finnie sees biggest opportunity in undervalued US cannabis companies NORWOOD,.
HENDERSON, NV / ACCESSWIRE / November 6, 2018 / As the stock market plummeted early October cannabis companies stayed strong, buoyed up by legislative changes in Canada. The cannabis market appears set ...
The legalization of medical marijuana and recreational marijuana have emerged as key talking points in the run up to the election. Seven states have already legalized recreational marijuana, while roughly 30 other states have passed medical cannabis in some form. On Tuesday, four more states could be added to those lists. Legalization of the drug for recreational use is on the ballot in North Dakota and Michigan, while voters in Missouri and Utah will decide whether to legalize cannabis for medical purposes.
U.S.-based MariMed bucked the downtrend in the cannabis sector last month. Here's what investors should know.
In-depth discussion of Medical Marijuana Research and PracticeFeatured speakers Dr. Jokūbas Žiburkus (Canntelligence), Dr. Dustin Sulak (Healer.com),Panel hosted by CNBC’s.
Naturally, this has significant implications for marijuana stocks. Favorable legislation stateside and in Canada boosted marijuana stocks like Tilray (NASDAQ:TLRY) into the stratosphere. While the pain is extremely pronounced for pot stocks, I believe the political environment presents high-risk/high-reward contrarian opportunities.
MariMed Inc., a multi-state cannabis organization that develops, owns and manages cannabis facilities and branded products lines, announced today that it has finalized the acquisition of BSC Group, a highly respected cannabis firm headquartered in New Jersey that over the last three years has been engaged in competitive licensing, consulting and operations management across the country. BSC founders and managing partners, Brian Staffa and Amber Staffa, will join the MariMed leadership team, bringing under the MariMed umbrella their extensive cannabis expertise, resources, intellectual property and a vast network of highly specialized affiliates spanning regulated fields of commercial cannabis, food and beverage, commercial agriculture, pharmaceuticals, regulatory compliance, consumer psychology, and the applied sciences.
HENDERSON, NV / ACCESSWIRE / October 24, 2018 / While many equities took losses on Tuesday one stock we found nearly doubled its price on the heels of some huge news. OriginClear, Inc. (OCLN) started what ...
U.S. Marijuana Index, compiled by Marijuana International Corporation, has delivered 158% returns over the past one year, as of October 17, 2018. Though the market saw a lot of volatility in marijuana policy during the course of the year on account of hard line policy stance taken by the new U.
Fireman, CEO of 2018 Top Performing Cannabis Stock, will share insight on MariMed, U.S. cannabis market opportunity NEWTON, MA and TORONTO, Oct. 17, 2018 -- MariMed Inc..
HENDERSON NV / ACCESSWIRE / October 11, 2018 / Some of the world's biggest beverage makers are looking to add cannabis-infused drinks to their lineups. Corona brewer Constellation Brands said last month ...
NEW YORK, NY / ACCESSWIRE / October 11, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...
CORAL GABLES, FL / ACCESSWIRE / October 5, 2018 / The cannabis market is attracting many new investors recently and the upcoming Canadian legalization has spawned added growth for marijuana stocks. The Drug Enforcement Administration recently placed Epidiolex, a drug that includes cannabis-derived compounds - specifically, cannabidiol (CBD) - in Schedule V. The DEA move takes a broad look at how the FDA is conducting its business, placing "certain drug products that have been approved by the [FDA] and which contain [CBD] in schedule V of the Controlled Substances Act (CSA)," according to the DEA order.